Claims
- 1- A hybrid meganuclease comprising a first domain and a second domain in the orientation N-terminal toward C-terminal, said first and second domains being derived from two different initial dodecapeptide meganucleases and wherein said hybrid meganuclease is capable of causing DNA cleavage.
- 2- Hybrid meganuclease according to claim 1, wherein said first domain is derived from a first di-dodecapeptide meganuclease and said second domain is derived from a second di-dodecapeptide meganuclease, said first and second domains being bound by a convenient linker.
- 3- Hybrid meganuclease according to claim 1, wherein said first domain is derived from a mono-dodecapeptide meganuclease and said second domain is derived from a di-dodecapeptide meganuclease, said first and second domains being bound by a convenient linker.
- 4- Hybrid meganuclease according to claim 1, wherein said first domain is derived from a di-dodecapeptide meganuclease and said second domain is derived from a mono-dodecapeptide meganuclease, said first and second domains being bound by a convenient linker.
- 5- Hybrid meganuclease according to claim 1, wherein said first domain is derived from a mono-dodecapeptide meganuclease and said second domain is derived from another mono-dodecapeptide meganuclease, said first and second domains being bound by a convenient linker.
- 6- Hybrid meganuclease according to claim 2, wherein said first domain is derived from the N-terminal domain of said first di-dodecapeptide meganuclease and said second domain is derived from the C-terminal domain of said second di-dodecapeptide meganuclease.
- 7- Hybrid meganuclease according to claim 2, wherein said first domain is derived from the N-terminal domain of said first di-dodecapeptide meganuclease and said second domain is derived from the N-terminal domain of said second di-dodecapeptide meganuclease.
- 8- Hybrid meganuclease according to claim 2, wherein said first domain is derived from the C-terminal domain of said first di-dodecapeptide meganuclease and said second domain is derived from the C-terminal domain of said second di-dodecapeptide meganuclease.
- 9- Hybrid meganuclease according to claim 2, wherein said first domain is derived from the C-terminal domain of said first di-dodecapeptide meganuclease and said second domain is derived from the N-terminal domain of said second di-dodecapeptide meganuclease.
- 10- Hybrid meganuclease according to claim 3, wherein said second domain is derived from the N-terminal domain of said di-dodecapeptide meganuclease.
- 11- Hybrid meganuclease according to claim 3, wherein said second domain is derived from the C-terminal domain of said di-dodecapeptide meganuclease.
- 12- Hybrid meganuclease according to claim 4, wherein said first domain is derived from the N-terminal domain of said di-dodecapeptide meganuclease.
- 13- Hybrid meganuclease according to claim 4, wherein said first domain is derived from the C-terminal domain of said di-dodecapeptide meganuclease.
- 14- Hybrid meganuclease according to any of claims 6, 7, and 12, wherein said convenient linker comprises a loop derived from said first di-dodecapeptide meganuclease or a part thereof.
- 15- Hybrid meganuclease according to any of claims 6, 8, and 11, wherein said convenient linker comprises a loop derived from said second di-dodecapeptide meganuclease or a part thereof.
- 16- Hybrid meganuclease according to claim 1, wherein said dodecapeptide meganuclease is selected from the group consisting of: I-Sce I, I-Chu I, I-Dmo I, I-Cre I, I-Csm I, PI-Sce I, PI-Tli I, PI-Mtu I, I-Ceu I, I-Sce II, I-Sce III, HO, PI-Civ I, PI-Ctr I, PI-Aae I, PI-Bsu I, PI-Dha I, PI-Dra I, PI-Mav I, PI-Mch I, PI-Mfu I, PI-Mfl I, PI-Mga I, PI-Mgo I, PI-Min I, PI-Mka I, PI-Mle I, PI-Mma I, PI-Msh I, PI-Msm I, PI-Mth I, PI-Mtu I, PI-Mxe I, PI-Npu I, PI-Pfu I, PI-Rma I, PI-Spb I, PI-Ssp I, PI-Fac I, PI-Mja I, PI-Pho I, PI-Tag I, PI-Thy I, PI-Tko I, and PI-Tsp I; preferably, I-Sce I, I-Chu I, I-Dmo I, I-Cre I, I-Csm I, PI-Pfu I, PI-Sce I, PI-Tli I, PI-Mtu I, I-Ceu I, I-Sce II, I-Sce III, and HO.
- 17- Hybrid meganuclease according to claim 1, wherein said dodecapeptide meganuclease is selected from the group consisting of: I-Sce I, I-Chu I, I-Dmo I, I-Cre I, I-Csm I, PI-Sce I, PI-Pfu I, PI-Tli I, PI-Mtu I, and I-Ceu I.
- 18- Hybrid meganuclease according to claim 4, wherein said di-dodecapeptide meganuclease is I-Dmo I and said mono-dodecapeptide meganuclease is I-Cre I.
- 19- Hybrid meganuclease according to claim 18, wherein said hybrid meganuclease comprises the sequence of SEQ ID No 4.
- 20- A hybrid meganuclease comprising a first and a second domains in the orientation N-terminal toward C-terminal, wherein each domain are derived from the same di-dodecapeptide meganuclease and said first domain is derived from the C-terminal domain and said second domain is derived from the N-terminal domain and wherein said hybrid meganuclease is capable of causing DNA cleavage.
- 21- A single-chain meganuclease comprising a first and a second domain in the orientation N-terminal toward C-terminal, wherein said first and second domains are derived from the same mono-dodecapeptide meganuclease and wherein said single-chain meganuclease is capable of causing DNA cleavage.
- 22- Single-chain meganuclease according to claim 21, wherein said mono-dodecapeptide meganuclease is I-Cre.
- 23- Single-chain meganuclease according to claim 24, wherein said single-chain meganuclease comprises the sequence of SEQ ID No 6.
- 24- A purified or recombinant polynucleotide encoding a meganuclease according to any of claims 1, 20 and 21.
- 25- A vector comprising a polynucleotide according to claim 24.
- 26- A host cell comprising a polynucleotide according to claim 24.
Parent Case Info
[0001] The present application is based on and claims benefit of U.S. application Serial No. 60/364,113, filed Mar. 15, 2002, the entire contents of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60364113 |
Mar 2002 |
US |